Induction of humoral and enhanced cellular immune responses by novel core-shell nanosphere- and microsphere-based vaccine formulations following systemic and mucosal administration

被引:31
作者
Caputo, Antonella [1 ]
Castaldello, Arianna
Brocca-Cofano, Egidio
Voltan, Rebecca
Bortolazzi, Francesca
Altavilla, Giuseppe [2 ]
Sparnacci, Katia [3 ,4 ]
Laus, Michele [3 ,4 ]
Tondelli, Luisa [5 ]
Gavioli, Riccardo [6 ]
Ensoli, Barbara [7 ]
机构
[1] Univ Padua, Microbiol Sect, Dept Histol Microbiol & Med Biotechnol, I-35122 Padua, Italy
[2] Univ Padua, Dept Med Diagnost Sci & Special Therapies, I-35122 Padua, Italy
[3] Univ Piemonte Orientale, Dept Life & Ambient Sci, I-15100 Alessandria, Italy
[4] UdR Piemonte Orientale, INSTM, I-15100 Alessandria, Italy
[5] CNR, ISOF, I-40129 Bologna, Italy
[6] Univ Ferrara, Dept Biochem & Mol Biol, I-44100 Ferrara, Italy
[7] Ist Super Sanita, Natl AIDS Ctr, I-00161 Rome, Italy
关键词
Functional core-shell nano- and microspheres; Antigen surface adsorption; HIV-1 Tat vaccine; Mice; HIV-1 TAT PROTEIN; CYTOTOXIC T-LYMPHOCYTES; POTENT DELIVERY-SYSTEM; DNA VACCINES; CATIONIC MICROPARTICLES; NEUTRALIZING ANTIBODIES; POLYMERIC MICROSPHERES; COATED NANOPARTICLES; LIPOPEPTIDE MALP-2; CYNOMOLGUS MONKEYS;
D O I
10.1016/j.vaccine.2009.03.047
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
071005 [微生物学]; 100108 [医学免疫学];
摘要
Anionic surfactant-free polymeric core-shell nanospheres and microspheres were previously described with an inner core constituted by poly(methylmethacrylate) (PMMA) and a highly hydrophilic outer shell composed of a hydiosoluble co-polymer (Eudragit L100-55). The outer shell is tightly linked to the core and bears carboxylic groups capable of adsorbing high amounts (antigen loading ability of up to 20%, w/w) of native basic proteins, mainly by electrostatic interactions, while preserving their activity. In the present study we have evaluated in mice the safety and immunogenicity of new vaccine formulations composed of these nano- and microspheres and the HIV-1 Tat protein. Vaccines were administered by different routes, including intramuscular, subcutaneous or intranasal and the results were compared to immunization with Tat alone or with Tat delivered with the alum adjuvant. The data demonstrate that the nano- and microspheres/Tat formulations are safe and induce robust and long-lasting cellular and humoral responses in mice after systemic and/or mucosal immunization. These delivery systems may have great potential for novel Tat protein-based vaccines against HIV-1 and hold promise for other protein-based vaccines. (C) 2009 Elsevier Ltd. All rights reserved.
引用
收藏
页码:3605 / 3615
页数:11
相关论文
共 58 条
[1]
Surfactant-free anionic PLA nanoparticles coated with HIV-1 p24 protein induced enhanced cellular and humoral immune responses in various animal models [J].
Ataman-Onal, Yasemin ;
Munier, Severine ;
Ganee, Arnaud ;
Terrat, Celine ;
Durand, Pierre-Yves ;
Battail, Nicole ;
Martinon, Frederic ;
Le Grand, Roger ;
Charles, Marie-Helene ;
Delair, Thierry ;
Verrier, Bernard .
JOURNAL OF CONTROLLED RELEASE, 2006, 112 (02) :175-185
[2]
Efficient mucosal delivery of the HIV-1 Tat protein using the synthetic lipopeptide MALP-2 as adjuvant [J].
Borsutzky, S ;
Fiorelli, V ;
Ebensen, T ;
Tripiciano, A ;
Rharbaoui, F ;
Scoglio, A ;
Link, C ;
Nappi, F ;
Morr, M ;
Buttó, S ;
Cafaro, A ;
Mühlradt, PF ;
Ensoli, B ;
Guzmán, CA .
EUROPEAN JOURNAL OF IMMUNOLOGY, 2003, 33 (06) :1548-1556
[3]
Efficient systemic and mucosal responses against the HIV-1 Tat protein by prime/boost vaccination using the lipopeptide MALP-2 as adjuvant [J].
Borsutzky, S ;
Ebensen, T ;
Link, C ;
Becker, PD ;
Fiorelli, V ;
Cafaro, A ;
Ensoli, B ;
Guzmán, CA .
VACCINE, 2006, 24 (12) :2049-2056
[4]
Particulate delivery systems for vaccines: what can we expect? [J].
Bramwell, Vincent W. ;
Perrie, Yvonne .
JOURNAL OF PHARMACY AND PHARMACOLOGY, 2006, 58 (06) :717-728
[5]
Candidate HIV-1 gpl40ΔV2, gag and tat vaccines protect against experimental HIV-1/MuLV challenge [J].
Brave, Andreas ;
Hinkula, Jorma ;
Cafaro, Aurelio ;
Eriksson, Lars E. ;
Srivastava, Indresh K. ;
Magnani, Mauro ;
Ensoli, Barbara ;
Barnett, Susan W. ;
Wahren, Britta ;
Rollman, Erik .
VACCINE, 2007, 25 (39-40) :6882-6890
[6]
Control of SHIV-89.6P-infection of cynomolgus monkeys by HIV-1 Tat protein vaccine [J].
Cafaro, A ;
Caputo, A ;
Fracasso, C ;
Maggiorella, MT ;
Goletti, D ;
Baroncelli, S ;
Pace, M ;
Sernicola, L ;
Koanga-Mogtomo, ML ;
Betti, M ;
Borsetti, A ;
Belli, R ;
Åkerblom, L ;
Corrias, F ;
Buttò, S ;
Heeney, J ;
Verani, P ;
Titti, F ;
Ensoli, B .
NATURE MEDICINE, 1999, 5 (06) :643-650
[7]
Recent advances in the development of HIV-1 Tat-based Vaccines [J].
Caputo, A ;
Gavioli, R ;
Ensoli, B .
CURRENT HIV RESEARCH, 2004, 2 (04) :357-376
[8]
Novel biocompatible anionic polymeric microspheres for the delivery of the HIV-1 Tat protein for vaccine application [J].
Caputo, A ;
Brocca-Cofano, E ;
Castaldello, A ;
De Michele, R ;
Altavilla, G ;
Marchisio, M ;
Gavioli, R ;
Rolen, U ;
Chiarantini, L ;
Cerasi, A ;
Dominici, S ;
Magnani, M ;
Cafaro, A ;
Sparnacci, K ;
Laus, M ;
Tondelli, L ;
Ensoli, B .
VACCINE, 2004, 22 (21-22) :2910-2924
[9]
Immunization with low doses of HIV-1 tat DNA delivered by novel cationic block copolymers induces CTL responses against Tat [J].
Caputo, A ;
Gavioli, R ;
Altavilla, G ;
Brocca-Cofano, E ;
Boarini, C ;
Betti, M ;
Castaldello, A ;
Lorenzini, F ;
Micheletti, F ;
Cafaro, A ;
Sparnacci, K ;
Laus, M ;
Tondelli, L ;
Ensoli, B .
VACCINE, 2003, 21 (11-12) :1103-1111
[10]
Characterization of immune responses elicited in mice by intranasal co-immunization with HIV-1 Tat, gp 140 ΔV2Env and/or SIV Gag proteins and the nontoxicogenic heat-labile Escherichia coli enterotoxin [J].
Caputo, Antonella ;
Brocca-Cofano, Egidio ;
Castaldello, Arianna ;
Voltan, Rebecca ;
Gavioli, Riccardo ;
Srivastava, Indresh K. ;
Barnett, Susan W. ;
Cafaro, Aurelio ;
Ensoli, Barbara .
VACCINE, 2008, 26 (09) :1214-1227